Assessing benefits and harms of cannabis use in patients treated with immunotherapy for cancer: a prospective cohort study

评估接受癌症免疫治疗的患者使用大麻的益处和危害:一项前瞻性队列研究

基本信息

  • 批准号:
    10792109
  • 负责人:
  • 金额:
    $ 67.64万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-09-15 至 2028-08-31
  • 项目状态:
    未结题

项目摘要

Project Abstract Up to 40% of patients report using cannabis for symptom management during and after cancer treatments despite gaps in our understanding of its longitudinal therapeutic uses and harms. Simultaneously, immuno- oncology is a rapidly advancing field of cancer treatment. Nearly 44% of cancer patients across 20 tumor types receive treatments with immunotherapy, notably Immune Checkpoint Inhibitors (ICIs), which can lead to persistent changes in the immune system for months or even years. Given cannabis also has immunomodulatory effects, there is a critical need to generate long-term data on the impact of cannabis use on longitudinal benefits and harms, immune function, and disease progression in cancer patients treated with ICIs. This proposal builds upon our existing program of research. Our team has conducted 4 NCI-funded projects regarding cannabis use in cancer patients, including 3 large cross-sectional surveys of cannabis use among patients treated at 3 NCI designated cancer centers. Across sites, 26% (n=831 of 3,169) of cancer patients reported using cannabis during treatment. However, the rate was considerably higher among patients treated with immunotherapy (32%). The overarching goal of this study is to advance the science regarding the longitudinal benefits and harms of cannabis use among those treated with ICIs for cancer. We propose a multi-site, 12-month prospective cohort study (N=450; 150 per site) with cancer patients treated with ICI (within 3 months): 225 cannabis users (regular weekly use in the prior month) and 225 cannabis non-users (no use in the past 6 months). Cannabis use, benefits, and harms will be assessed via ecological momentary assessment (collected 7 days/time point; 49 days total), patient reported outcomes will be assessed via online/phone surveys, and routine clinical data will be extracted from electronic medical records. Among a subset of 60 patients who have not yet started ICI treatment (30 cannabis users; 30 non-users), we will examine immunological markers (e.g., TNF-α, IL-6, CRP) at baseline (prior to starting ICI), 2, 6, & 12 months. The Specific Aims are to: 1) assess benefits (pain severity & interference, sleep disturbance, anxiety, quality of life) and harms (difficulty concentrating, impaired memory, dizziness, fatigue) of cannabis use over time; 2) test whether cannabis use over time moderates the associations between neighborhood disadvantage (Area Deprivation Index) and benefits and harms in Aim 1; & 3) among a subset of 60 patients with non-skin solid malignancies who have not yet started ICI, explore the association of cannabis use with disease progression and immunological markers. This timely and comprehensive study, in response to RFA-CA-22-052, will fill critical gaps in knowledge about longitudinal benefits and harms of cannabis use in persons treated with ICIs. The strong multidisciplinary team brings the requisite expertise in cancer symptom management, medical cannabis, health equity, oncology, immunology, and substance misuse. In collaboration with other funded U01s and U24, this research will have a sustained impact on the science of cancer symptom management and ultimately improve patient care and safety.
项目摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Rebecca Ashare其他文献

Rebecca Ashare的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Rebecca Ashare', 18)}}的其他基金

Cannabis use and outcomes in ambulatory patients with cancer: A 12-month cohort study
门诊癌症患者的大麻使用和结果:一项为期 12 个月的队列研究
  • 批准号:
    10818686
  • 财政年份:
    2022
  • 资助金额:
    $ 67.64万
  • 项目类别:
Cannabis use and outcomes in ambulatory patients with cancer: A 12-month cohort study
门诊癌症患者的大麻使用和结果:一项为期 12 个月的队列研究
  • 批准号:
    10610465
  • 财政年份:
    2022
  • 资助金额:
    $ 67.64万
  • 项目类别:
Determinants and Outcomes of Nicotine Metabolite Ratio in HIV + Smokers
HIV 吸烟者尼古丁代谢比率的决定因素和结果
  • 批准号:
    10330407
  • 财政年份:
    2020
  • 资助金额:
    $ 67.64万
  • 项目类别:
Determinants and Outcomes of Nicotine Metabolite Ratio in HIV + Smokers
HIV 吸烟者尼古丁代谢比率的决定因素和结果
  • 批准号:
    10573496
  • 财政年份:
    2020
  • 资助金额:
    $ 67.64万
  • 项目类别:
Determinants and Outcomes of Nicotine Metabolite Ratio in HIV + Smokers
HIV 吸烟者尼古丁代谢比率的决定因素和结果
  • 批准号:
    9927113
  • 财政年份:
    2020
  • 资助金额:
    $ 67.64万
  • 项目类别:
Targeting the Cholinergic Pathway in HIV-associated Inflammation and Cognitive Dysfunction
针对 HIV 相关炎症和认知功能障碍的胆碱能通路
  • 批准号:
    10201539
  • 财政年份:
    2017
  • 资助金额:
    $ 67.64万
  • 项目类别:
Targeting the Cholinergic Pathway in HIV-associated Inflammation and Cognitive Dysfunction
针对 HIV 相关炎症和认知功能障碍的胆碱能通路
  • 批准号:
    9413656
  • 财政年份:
    2017
  • 资助金额:
    $ 67.64万
  • 项目类别:
Repurposing Melatonin Receptor Agonists as Adjunct Treatments for Smoking Cessation
重新利用褪黑激素受体激动剂作为戒烟的辅助治疗
  • 批准号:
    9014081
  • 财政年份:
    2015
  • 资助金额:
    $ 67.64万
  • 项目类别:
Repurposing Melatonin Receptor Agonists as Adjunct Treatments for Smoking Cessation
重新利用褪黑激素受体激动剂作为戒烟的辅助治疗
  • 批准号:
    9144346
  • 财政年份:
    2015
  • 资助金额:
    $ 67.64万
  • 项目类别:
Repurposing cholinesterase inhibitors for smoking cessation
重新利用胆碱酯酶抑制剂来戒烟
  • 批准号:
    9233957
  • 财政年份:
    2013
  • 资助金额:
    $ 67.64万
  • 项目类别:

相似海外基金

Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
  • 批准号:
    MR/X034690/1
  • 财政年份:
    2024
  • 资助金额:
    $ 67.64万
  • 项目类别:
    Fellowship
Clinitouch-360: A digital health platform enabling robust end-to-end care of patients in Primary Care with depression and anxiety
Clinitouch-360:数字健康平台,可为初级保健中的抑郁和焦虑患者提供强大的端到端护理
  • 批准号:
    10098274
  • 财政年份:
    2024
  • 资助金额:
    $ 67.64万
  • 项目类别:
    Collaborative R&D
Mental Health and Occupational Functioning in Nurses: An investigation of anxiety sensitivity and factors affecting future use of an mHealth intervention
护士的心理健康和职业功能:焦虑敏感性和影响未来使用移动健康干预措施的因素的调查
  • 批准号:
    10826673
  • 财政年份:
    2024
  • 资助金额:
    $ 67.64万
  • 项目类别:
Visual analysis system to detect and predict the signs of anxiety in healthcare
用于检测和预测医疗保健中焦虑迹象的视觉分析系统
  • 批准号:
    2902083
  • 财政年份:
    2024
  • 资助金额:
    $ 67.64万
  • 项目类别:
    Studentship
Using generative AI combined with immersive technology to treat anxiety disorders
利用生成式人工智能结合沉浸式技术治疗焦虑症
  • 批准号:
    10109165
  • 财政年份:
    2024
  • 资助金额:
    $ 67.64万
  • 项目类别:
    Launchpad
Healthy Young Minds: co-producing a nature-based intervention with rural High School students to promote mental well-being and reduce anxiety
健康的年轻心灵:与农村高中生共同开展基于自然的干预措施,以促进心理健康并减少焦虑
  • 批准号:
    MR/Z503599/1
  • 财政年份:
    2024
  • 资助金额:
    $ 67.64万
  • 项目类别:
    Research Grant
"Flashforward" imagery and anxiety in young adults: Risk mechanisms and intervention development
年轻人的“闪现”意象和焦虑:风险机制和干预措施的发展
  • 批准号:
    MR/Y009460/1
  • 财政年份:
    2024
  • 资助金额:
    $ 67.64万
  • 项目类别:
    Fellowship
How parents manage climate anxiety: coping and hoping for the whole family
父母如何应对气候焦虑:全家人的应对和希望
  • 批准号:
    DP230101928
  • 财政年份:
    2024
  • 资助金额:
    $ 67.64万
  • 项目类别:
    Discovery Projects
An innovative biofeedback enhanced adaptive extended reality (XR) device to reduce perinatal pain and anxiety during and after childbirth
一种创新的生物反馈增强型自适应扩展现实 (XR) 设备,可减少分娩期间和分娩后的围产期疼痛和焦虑
  • 批准号:
    10097862
  • 财政年份:
    2024
  • 资助金额:
    $ 67.64万
  • 项目类别:
    Collaborative R&D
Application name Phase Space - VR hypnotherapy as early intervention for anxiety in students and young people
应用程序名称 Phase Space - VR 催眠疗法作为学生和年轻人焦虑的早期干预
  • 批准号:
    10055011
  • 财政年份:
    2023
  • 资助金额:
    $ 67.64万
  • 项目类别:
    Collaborative R&D
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了